Ranbaxy API Plant Given FDA Warning

Ranbaxy's active pharmaceutical ingredient (API) manufacturing factory in Toansa, Punjab has received a Form 483 warning from the US FDA, communicating concerns discovered during last week's inspection.

As Ranbaxy's main API factory, the Toansa facility supplies about 70% of the raw ingredients for production, including supplying to Ranbaxy's Ohm Laboratories plant in New Jersey.

Other India-based Ranbaxy factories — at Paonta Sahib (Himachal Pradesh), Dewas (Madhya Pradesh) and Mohali (Punjab) — are already barred from exporting drugs to the US.

In a press statement, Ranbaxy said it will assess the observations and respond to the FDA.

Read the Business Standard press release

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments